Opus Genetics (R3X1) Stock Overview
A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
R3X1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Opus Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.52 |
| 52 Week High | US$2.52 |
| 52 Week Low | US$0.57 |
| Beta | 0.59 |
| 1 Month Change | 53.17% |
| 3 Month Change | 48.99% |
| 1 Year Change | 127.81% |
| 3 Year Change | -16.47% |
| 5 Year Change | -73.24% |
| Change since IPO | -33.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| R3X1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 31.5% | -1.1% | 0.4% |
| 1Y | 127.8% | -22.4% | 7.9% |
Return vs Industry: R3X1 exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: R3X1 exceeded the German Market which returned 8% over the past year.
Price Volatility
| R3X1 volatility | |
|---|---|
| R3X1 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: R3X1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R3X1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 18 | George Magrath | opusgtx.com |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
Opus Genetics, Inc. Fundamentals Summary
| R3X1 fundamental statistics | |
|---|---|
| Market cap | €175.59m |
| Earnings (TTM) | -€57.69m |
| Revenue (TTM) | €12.38m |
Is R3X1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R3X1 income statement (TTM) | |
|---|---|
| Revenue | US$14.63m |
| Cost of Revenue | US$27.42m |
| Gross Profit | -US$12.78m |
| Other Expenses | US$55.42m |
| Earnings | -US$68.20m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | -87.37% |
| Net Profit Margin | -466.09% |
| Debt/Equity Ratio | 17.9% |
How did R3X1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 12:10 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Opus Genetics, Inc. is covered by 10 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |